Press releases

Share this press release :  facebook  twitter  linkedin  google+
Quantum Genomics to Host Key Opinion Leader Event Focused on Phase IIa Hypertension Data and the Upcoming Clinical Trial in the United States   (23/05/2017 18:00)

Paris & New York, May 23, 2017

Quantum Genomics to Host Key Opinion Leader Event Focused on Phase IIa Hypertension Data and the Upcoming Clinical Trial in the United States

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular announced today that it will host a Key Opinion Leader (KOL) event for institutional investors and research analysts on June 27, 2017, in New York, NY, focused around discussing the Phase IIa results in hypertension and the upcoming clinical trial in the United States.

Lionel Ségard, President and Chief Executive Officer of Quantum Genomics and Dr. Bruno Besse, Chief Medical Officer of Quantum Genomics, will present the data and analysis of the Phase IIa study in hypertension, along with the next clinical trial.

This event will feature presentations by prominent academic physicians:

  • Keith C. Ferdinand, M.D., Professor of Medicine at the Tulane School of Medicine and former Chair of the National Forum for Heart Disease and Stroke Prevention.
  • Henry Black, M.D., Adjunct Professor of Medicine and member of the Section of Cardiology at the New York University School of Medicine and President Emeritus of the American Society of Hypertension.

A panel discussion moderated by Max Jacobs of Edison Investment Research will follow.

Event: Quantum Genomics KOL & Investor Day

Date: Tuesday, June 27th, 2017

Time: 11:00am - 2:00pm (Eastern Time)

Location: Le Parker Meridien, New York, NY

A webcast will be recorded and made available on Quantum Genomics' website at www.quantum-genomics.com


 


ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.


CONTACTS
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
 
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
 
ACTUS finance & communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr
 
Edison Advisors (U.S.)
Tirth Patel
Investor Relations
+1 (646) 653-7035
tpatel@edisongroup.com



Powered by Actusnews Wire (press release services) ©